References

Abramson HA, Jarvik ME, Levine A, Kaufman MR, Hirsch MW (1955) Lysergic acid diethylamide (LSD-25): XV. The effects produced by substitution of a tap water placebo. Journal of Psychology 40:367–383.

Arasteh K, Poudevida S, Farré M, Roset PN, Camí J (1999) Response patterns of the spanish version of the 49-item short form of the addiction research center inventory after the use of sedatives, stimulants, and opioids. Drug and Alcohol Dependence 55:117–125.

Barrett FS, Johnson MW, Griffiths RR (2015) Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology.

Bodmer I (1989) Konstruktion des fragebogens OAV zur quantitativen erfassung aussergewöhnlicher bewusstseinszustände (ABZ) [construction of the questionnaire OAV for the quantitative assessment of altered states of consciousness].

Bodmer I, Dittrich A, Lamparter D (1994) Aussergewöhnliche bewusstseinszustände - ihre gemeinsame struktur und messung [altered states of consciousness - their common structure and assessment]. In: Welten des bewusstseins. Bd. 3 (Hofmann A, Leuner H, eds), pp 45–58. Berlin, Germany: Experimentelle Psychologie, Neurobiologie und Chemie.

Bouso JC, Pedrero-Perez EJ, Candy S, Alcazar-Corcoles MA (2016) Measuring the subjective: Revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens. Journal of Clinical Psychiatry:391–393.

Bowdle T, Radant A, Cowley D, Kharasch E, Strassman R, Roy-Byrne P (1998) Psychedelic effects of ketamine in healthy volunteers: Relationship to steady-state plasma concentrations.

Carhart-Harris R et al (2016) Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci.

Carhart-Harris R, Kaelen M, Bolstridge M, Williams T, Williams L, Underwood R, Feilding A, Nutt D (2016) The paradoxical psychological effects of lysergic acid diethylamide (LSD). :1379–1390.

Daniel C, Lovatt A, Mason O (2014) Psychotic-like experiences and their cognitive appraisal under short-term sensory deprivation. Front Psychiatry 5:106.

Daniel C, Mason O (2015) Predicting psychotic-like experiences during sensory deprivation. Biomed Res Int 2015.

Davis AK, Barrett FS, So S, Gukasyan N, Swift TC, Griffiths RR (2021) Development of the psychological insight questionnaire among a sample of people who have consumed psilocybin or LSD. Journal of Psychopharmacology 35:437–446 Available at: https://doi.org/10.1177/0269881120967878.

Dittrich A (1985) Ätiologie-unabhängige strukturen veränderter wachbewusstseinszustände.

Dittrich A, Lamparter D, Maurer M (2006) 5D-ABZ: Fragebogen zur erfassung aussergewöhnlicher bewusstseinszustände. Eine kurze einführung. Zürich, Switzerland.

Dittrich A, Lamparter D, Maurer M (2010) 5D-ASC: Questionnaire for the assessment of altered states of consciousness. A short introduction (3rd ed.). Zürich, Switzerland: PSIN PLUS.

Doblin R (1991) Pahnke’s “good friday experiment” - a long-term follow-up and methodological critique. J Transpers Psychol 23:1–28.

Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar K, Hermle L, Bull U, Sass H (1999) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 20:565–581.

Greyson B (1983) The near-death experience scale: Construction, reliability, and validity. Journal of Nervous and Mental Disease 171:369–375 Available at: https://doi.org/10.1097/00005053-198306000-00007.

Griffiths R, Johnson M, Richards W, Richards B, McCann U, Jesse R (2011) Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology (Berl) 218:649–665.

Griffiths R, Richards W, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187:268-283-292.

Haertzen C (1974) An overview of addiction research center inventory scales (ARCI): Appendix and manual of scales. Rockville: National Institute of Drug Abuse.

Haertzen C, Hickey J (1987) Addiction research center inventory (ARCI): Measurement of euphoria and other drug effects. In: Methods of assessing the reinforcing properties of abused drugs (Bozarth M, ed), pp 489–524. New York: Springer.

Haertzen C, Hill H, Belleville R (1963) Development of the addiction research center inventory (ARCI): Selection of items that are sensitive to the effects of various drugs. Psychopharmacologia 4:155–166.

Hill H, Haertzen C, Wolbach A, Miner E (1963a) The addictive research center inventory: Appendix i. Items comprising empirical scales for seven drugs II. Items which do not differentiate placebo from any drug condition. Psychopharmacologia 4:184–205.

Hill H, Haertzen C, Wolbach A, Miner E (1963b) The addiction research center inventory: Standardization of scales which evaluate subjective effects of morphine, amphetamine, pentobarbital, alcohol, LSD-25, pyrahexyl and chlorpromazine. Psychopharmacologia 4:167–183.

Hirschfeld T, Prugger J, Majić T, Schmidt TT (2023) Dose-response relationships of LSD-induced subjective experiences in humans. Neuropsychopharmacology 48:1602–1611 Available at: https://doi.org/10.1038/s41386-023-01588-2.

Hirschfeld T, Schmidt TT (2021) Dose-response relationships of psilocybin-induced subjective experiences in humans. Journal of Psychopharmacology 35:384–397 Available at: https://doi.org/10.1177/0269881121992676.

Hood R (1975) The construction and preliminary validation of a measure of reported mystical experience. J Sci Study Relig 14:29–41.

Hood R, Ghorbani N, Watson P, Ghramaleki A, Bing M, Davison H, Morris R, Williamson W (2001) Dimensions of the mysticism scale: Confirming the three-factor structure in the united states and iran. J Sci Study Relig 40:691–705.

James W (1901) Varieties of religious experience. New York: New American Library.

Jarvik ME, Abramson HA, Hirsch MW (1955) Comparative subjective effects of seven drugs including lysergic acid diethylamide (LSD-25). Journal of Abnormal Psychology 51:657–662 Available at: https://doi.org/10.1037/h0041073.

Jasinski D, Martin W, Hoeldtke R (1971) Studies of the dependence-producing properties of GPA-1657, profadol and proplram in man. Clin Pharmacol Ther 12:613–649.

Johnson M, MacLean K, Reissig C, Prisinzano T, Griffiths R (2011) Human psychopharmacology and dose-effects of salvinorin a, a kappa opioid agonist hallucinogen present in the plant salvia divinorum. Drug Alcohol Depend 115:150–155.

Kjellgren A, Lindahl A, Norlander T (2009) Altered states of consciousness and mystical experiences during sensory isolation in flotation tank: Is the highly sensitive personality variable of importance? IMAGINATION, Cogn Personal 29:135–146.

Kjellgren A, Sundequist U, Norlander T, Archer T (2001) Effects of flotation-REST on muscle tension pain. Pain Res Manag 6:181–189.

Lamas X, Farré M, Llorente M, Camí J (1994) Spanish version of the 49-item short form of the addiction research center inventory. Drug Alcohol Depend 35:203–209.

Lebedev A, Lövdén M, Rosenthal G, Feilding A, Nutt D, Carhart-Harris R (2015) Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin. Hum Brain Mapp 36:3137–3153.

Linton H, Langs R (1962) Placebo reaction in a study of lysergic acid diethylamide (LSD-25). Arch Gen Psychiatry.

MacLean K, Johnson M, Griffiths R (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25:1453–1461.

MacLean K, Leoutsakos J-M, Johnson M, Griffiths R (2012) Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig 51:721–737.

Majic T, Schmidt T, Gallinat J (2015) Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J Psychopharmacol 29:241–253.

Martin W, Sloan J, Sapira J, Jasinski D (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245–258.

Mason O, Brady F (2009) The psychotomimetic effects of short-term sensory deprivation. J Nerv Ment Dis 197:783–785.

Mason O, Morgan C, Stefanovic A, Curran H (2008) The psychotomimetic states inventory (PSI): Measuring psychotic-type experiences from ketamine and cannabis. Schizophr Res 103:138–142.

Nour M, Evans L, Nutt D, Carhart-Harris R (2016) Ego-dissolution and psychedelics: Validation of the ego-dissolution inventory (EDI). Front Hum Neurosci 10:269 Available at: http://www.ncbi.nlm.nih.gov/pubmed/27378878.

Pahnke WN (1963) Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness. Harvard University Press.

Pahnke WN (1966) Drugs and mysticism. Int J Parapsychol 8:295–314.

Peill JM, Trinci KE, Kettner H, Mertens LJ, Roseman L, Timmermann C, Rosas FE, Lyons T, Carhart-Harris RL (2022) Validation of the psychological insight scale: A new scale to assess psychological insight following a psychedelic experience. Journal of Psychopharmacology 36:31–45 Available at: https://doi.org/10.1177/02698811211066709.

Pekala R (1982) The phenomenology of consciousness inventory. Thorndale, PA: Psychophenomenological Concepts.

Pekala R (1991) Quantifying consciousness: An empirical approach. New York: Plenum Press.

Pekala R (1995) A short, unobtrusive hypnotic-assessment procedure for assessing hypnotizability level: I. Development and research. Am J Clin Hypn 37:271–283.

Riba J, Anderer P, Jané F, Saletu B, Barbanoj MJ (2004) Effects of the south american psychoactive beverage ayahuasca on regional brain electrical activity in humans: A functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology 50:89–101.

Riba J, Rodríguez-Fornells A, Strassman RJ, Barbanoj MJ (2001) Psychometric assessment of the hallucinogen rating scale. Drug Alcohol Depend 62:215–223.

Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R (2019) Emotional breakthrough and psychedelics: Validation of the emotional breakthrough inventory. Journal of Psychopharmacology 33:1076–1087 Available at: https://doi.org/10.1177/0269881119855974.

Rux (2002) Erprobung der deutschen übersetzung des phenomenology of consciousness inventory von pekala: Normwerte, gütekriterien, änderungsvorschläge.

Scharfetter C (1981) Ego-psychopathology: The concept and its empirical evaluation. Psychol Med 11:273–280.

Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Müller F, Borgwardt S, Liechti ME (2015) Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry 78:544–553.

Shor RE (1960) The frequency of naturally occurring “hypnotic-like” experiences in the normal college population. Int J Clin Exp Hypn 8:151–163.

Stocker K, Hartmann M, Ley L, Becker AM, Holze F, Liechti ME (2024) The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies. Journal of Psychopharmacology 38:80–100 Available at: https://doi.org/10.1177/02698811231199112.

Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose-response study of n,n-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98–108.

Strickland JC, Garcia-Romeu A, Johnson MW (2024) The mystical experience questionnaire 4-item and challenging experience questionnaire 7-item. Psychedelic Medicine 2:33–43.

Studerus E, Gamma A, Kometer M, Vollenweider FX (2012) Prediction of psilocybin response in healthy volunteers. PLoS One 7:e30800.

Studerus E, Gamma A, Vollenweider FX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV).

Tagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, Laufs H, Leech R, McGonigle J, Crossley N, Bullmore E, Williams T, Bolstridge M, Feilding A, Nutt DJ, Carhart-Harris R (2016) Increased global functional connectivity correlates with LSD-induced ego dissolution. Curr Biol 26:1043–1050.

Tancer ME, Johanson C-E (2007) The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacol 189:565–573.

Tart CT (1972) States of consciousness and state-specific sciences. Science 176:1203–1210.

Van Quekelberghe R, Altstötter-Gleich C, Hertweck E (1991) Assessment schedule for altered states of consciousness: A brief report. Journal of Parapsychology 55:377–390.

Van Quekelberghe R, Schreiber WH, Peter M, Caprano G (1992) Erfassungssystem veränderter bewußtseinszustände (EVB): Darstellung des verfahrens und der ergebnisse aus den vergleichsuntersuchungen zwischen normalen, heroinabhängigen, depressiven und schizophrenen. Forschungsberichte des FB Psychologie, Universität Koblenz-Landau.

Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci 11:642–651.

Warot D, Danjou P, Payan C, Puech AJ (1997) Sensitivity and specificity to amphetamine of a french version of the 49-item form of the addiction research center inventory. Drug Alcohol Depend 45:177–183.

Watts R, Kettner H, Geerts D, Gandy S, Kartner L, Mertens L, Timmermann C, Nour MM, Kaelen M, Nutt D, Carhart-Harris R, Roseman L (2022) The watts connectedness scale: A new scale for measuring a sense of connectedness to self, others, and world. Psychopharmacology (Berl) 239:3461–3483 Available at: https://doi.org/10.1007/s00213-022-06187-5.

Yeginer A (2000) Forschungsinstrumente der transpersonalen psychologie.